Commercialisation of SleepCogni into UK and US sleep clinic market

我们的睡眠量越来越被认为对我们的健康和福祉有重要影响。近年来，我们越来越意识到睡眠对我们身心健康的影响。即使是一个糟糕的睡眠或深夜也会影响一个人的情绪，警觉性和记忆力。睡眠不佳的长期影响会导致一系列危及生命的疾病，如心血管疾病、肥胖和抑郁症。美国疾病控制和预防中心（Centers for Disease Control and Prevention）最近将睡眠不足确定为一种全球流行病。睡眠不佳的经济成本巨大，导致每年生产力损失惊人：美国4110亿美元，日本1380亿美元，德国600亿美元，英国500亿美元。不出所料，睡眠辅助剂市场是全球性的，需求量大且不断增长，预计到2023年将达到1019亿美元，CARG占6.5%。（兰德欧洲，2016年）。我们的使命是让世界摆脱上瘾的安眠药，为每个人提供良好的睡眠，改善健康和福祉。SleepCogni已经确定了对辅助诊断的解决方案的迫切临床需求，提供治疗并监测依从性。SleepCogni系统为这一问题提供了创新的技术解决方案。SleepCogni开发了一种可穿戴和床边设备并获得专利，该设备旨在在受试者家中使用，通过纵向数据为睡眠临床医生提供支持，从而实现全面的诊断。它还可以通过生物反馈系统使用个性化的光、声音和触觉线索来治疗失眠。由于他们之前的英国创新基金，SleepCogni已经开始产生真实的动力。SleepCogni现在是（i）临床证明的治疗，（ii）FDA注册，（iii）已经招募了四个睡眠诊所进行测试。该项目将使SleepCogni进入开发的最后阶段，加速商业化并利用以前的投资。

The amount we sleep has been increasingly recognised as having an important impact on our health and well-being. Over recent years we have become increasingly aware of the effects that sleep has on both our physical and mental health. Even one bad night's sleep or late night can affect a person's mood, alertness and memory. The long-term effect of poor sleep can cause a range of life-threatening conditions such as cardiovascular disease, obesity and depression. Sleep deprivation was recently identified by Centers for Disease Control and Prevention as a global epidemic.The economic costs of poor sleep are huge and lead to a staggering annual productivity loss; US $411bn, Japan $138bn, Germany $60bn and UK $50bn. Unsurprisingly, the sleep aid market is global, demanding and growing, and expected to hit $101.9bn by 2023 with 6.5% CARG (RAND Europe, 2016).Our mission is to rid the world of addictive sleeping tablets and provide a good night's sleep for everyone, improving health and well-being.SleepCogni has identified an urgent clinical need for a solution that aids diagnostics, provides treatment and monitors adherence. The SleepCogni system provides an innovative technological solution to this problem. SleepCogni has developed and patented a wearable and bedside device designed to be used within a subject's home, which will provide support to sleep clinicians, through longitudinal data, enabling a fully informed diagnosis. It can also deliver a treatment for insomnia using light, sound and tactile cues personalised through a biofeedback system.Due to their previous Innovate UK grant, SleepCogni has started to generate real momentum. SleepCogni is now (i) a clinically proven treatment, (ii) FDA registered and (iii) has enrolled four sleep clinics for testing. This project would allow SleepCogni to move to the final stage of development, accelerating commercialisation and capitalising on previous investment.